Good news! Cancer is history (soon)!
"The progress of cancer vaccines has been limited by immune tolerance, variability in how well antibodies can attach to targets and modest clinical efficacy.
But recent advances in mRNA vaccines, better ability to predict cancer-specific targets and combination with immunotherapies are helping to make vaccines more precise and effective.
As of May 2025, there are 513 cancer vaccines in development, with most (47%) in early-stage development. Continued advancement will require more accurate ways to predict new proteins on cancer cells that can be targeted by antibodies, improved delivery systems and integration with other forms of therapy, suggest a group of health and drug researchers."
The landscape for therapeutic cancer vaccines (no public access)
a) All 513 vaccines were classified based on their mechanism, with most being peptide or dendritic cell vaccines. b) The graph shows the trial-stage breakdown of each vaccine type. c) Distribution of products by antigen type, including tumour-associated antigens (TAAs) and tumour-specific antigens (TSAs).
No comments:
Post a Comment